1h Free Analyst Time
The publisher's latest disease pipeline guide Deep Vein Thrombosis (DVT) - Drugs In Development, 2022, provides an overview of the Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline landscape.Speak directly to the analyst to clarify any post sales queries you may have.
Deep venous thrombosis is a blood clot that forms in a vein deep inside a part of the body. It mainly affects the large veins in the lower leg and thigh. Symptoms include changes in skin color (redness), leg pain, leg swelling (edema) and skin that feels warm to the touch. The predisposing factors include age, smoking, inheriting a blood-clotting disorder, injury or surgery, cancer, inflammatory bowel disease and heart failure. Treatment includes thrombolytic and anticoagulants.
Report Highlights
The publisher's latest pipeline guide Deep Vein Thrombosis (DVT) - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Deep Vein Thrombosis (DVT) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 7 and 1 respectively.
Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Deep Vein Thrombosis (DVT) (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Deep Vein Thrombosis (DVT) (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Deep Vein Thrombosis (DVT) (Cardiovascular)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Deep Vein Thrombosis (DVT) (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Deep Vein Thrombosis (DVT) (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
List of TablesList of Figures
Introduction
Report Coverage
Deep Vein Thrombosis (DVT) - Overview
Deep Vein Thrombosis (DVT) - Therapeutics Development
Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
Assesement by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Deep Vein Thrombosis (DVT) - Companies Involved in Therapeutics Development
Anthos Therapeutics Inc
Bio-Synectics Inc
CarboMimetics
China Resources Emde Biological Pharmaceutical Co Ltd
Glycan Therapeutics Inc
Guangzhou Dazhou Biomedical Technology Co Ltd
Kolmar Korea Co Ltd
Laboratorios Farmaceuticos Rovi SA
Marizyme Inc
Protheragen Inc
Suzhou Ribo Life Sciences Co Ltd
Tianjin Pharmaceuticals Group Co Ltd
Deep Vein Thrombosis (DVT) - Drug Profiles
abelacimab - Drug Profile
Product Description
Mechanism Of Action
History of Events
CM-20201 - Drug Profile
Product Description
Mechanism Of Action
enoxaparin sodium - Drug Profile
Product Description
Mechanism Of Action
History of Events
heparin - Drug Profile
Product Description
Mechanism Of Action
KKM-183A - Drug Profile
Product Description
Mechanism Of Action
MB-104 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Polysaccharide to Inhibit Coagulation Factor X for Deep Vein Thrombosis and Sickle Cell Disease - Drug Profile
Product Description
Mechanism Of Action
History of Events
reteplase - Drug Profile
Product Description
Mechanism Of Action
rivaroxaban - Drug Profile
Product Description
Mechanism Of Action
Small Molecule to Inhibit NMMHC IIA for Deep Vein Thrombosis - Drug Profile
Product Description
Mechanism Of Action
SR-059 - Drug Profile
Product Description
Mechanism Of Action
Zifa-01 - Drug Profile
Product Description
Mechanism Of Action
Deep Vein Thrombosis (DVT) - Dormant Projects
Deep Vein Thrombosis (DVT) - Discontinued Products
Deep Vein Thrombosis (DVT) - Product Development Milestones
Featured News
Sep 19, 2018: ROVI has commenced the marketing of its enoxaparin biosimilar in Spain
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
- Number of - Products under Development for Deep Vein Thrombosis (DVT), 2022
- Number of - Products under Development by Companies, 2022
- Products under Development by Companies, 2022
- Number of Products by Stage and Target, 2022
- Number of Products by Stage and Mechanism of Action, 2022
- Number of Products by Stage and Route of Administration, 2022
- Number of Products by Stage and Molecule Type, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Bio-Synectics Inc, 2022
Deep Vein Thrombosis (DVT) - Pipeline by CarboMimetics, 2022
Deep Vein Thrombosis (DVT) - Pipeline by China Resources Emde Biological Pharmaceutical Co Ltd, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Glycan Therapeutics Inc, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Guangzhou Dazhou Biomedical Technology Co Ltd, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Kolmar Korea Co Ltd, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Laboratorios Farmaceuticos Rovi SA, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Marizyme Inc, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Protheragen Inc, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Suzhou Ribo Life Sciences Co Ltd, 2022
Deep Vein Thrombosis (DVT) - Pipeline by Tianjin Pharmaceuticals Group Co Ltd, 2022
Deep Vein Thrombosis (DVT) - Dormant Projects, 2022
Deep Vein Thrombosis (DVT) - Dormant Projects, 2022 (Contd..1)
Deep Vein Thrombosis (DVT) - Discontinued Products, 2022
List of Figures
- Number of - Products under Development for Deep Vein Thrombosis (DVT), 2022
- Number of - Products under Development by Companies, 2022
- Number of Products by Targets, 2022
- Number of Products by Stage and Targets, 2022
- Number of Products by Mechanism of Actions, 2022
- Number of Products by Stage and Mechanism of Actions, 2022
- Number of Products by Routes of Administration, 2022
- Number of Products by Stage and Top 10 Routes of Administration, 2022
- Number of Products by Molecule Types, 2022
- Number of Products by Stage and Molecule Types, 2022
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Anthos Therapeutics Inc
- Bio-Synectics Inc
- CarboMimetics
- China Resources Emde Biological Pharmaceutical Co Ltd
- Glycan Therapeutics Inc
- Guangzhou Dazhou Biomedical Technology Co Ltd
- Kolmar Korea Co Ltd
- Laboratorios Farmaceuticos Rovi
